AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06615830
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will receive the standard first-line chemotherapy (chosen among Gemcitabine-Abraxane, or Abraxane-Gemcitabine-FOLFOX or FOLFIRINOX, based on the clinical judgement of the treating oncologist) until disease progression.
Trial: NCT06615830
Drug: Organoid-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upon disease progression confirmed radiologically, the patients will receive second-line chemotherapy. Second-line chemotherapy will be selected among the most promising effective drug (or drug regimens) as predicted in vitro by their benchmarking on patient-derived organoids.
Trial: NCT05259904
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 weeks of treatment with orally administered matching placebo (to 15 g/day of L-citrulline)
Trial: NCT06274853
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT04849013
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebo Capsules containing mannitol looking identical to the other drugs Other: Placebo Capsules containing mannitol looking identical to the other drugs
Trial: NCT05663372
Drug: Efez 50 mg eplerenone film-coated tablets
RxNorm normalized name: eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral, mineralocorticoid receptor antagonist, a blocker of aldosterone
Trial: NCT05663372
Drug: INSPRA® 50 mg eplerenone film-coated tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, mineralocorticoid receptor antagonist, a blocker of aldosterone
Trial: NCT06396637
Drug: Sapropterin Dihydrochloride
RxNorm normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sapropterin Dihydrochloride: 20mg/kg, qd
Trial: NCT04937829
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06613269
Drug: 68Ga-NY104 PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 68Ga-NY104 PET/CT will be performed at baseline, 6 months, 12 months, and 24 months after radiation therapy if the tumor is under control. If CT or MRI shows any suspicious recurrence or metastasis, 68Ga-NY104 PET/CT can be performed at the decision of the urology oncologist or radiation oncologist.~The scan begins 1 hour after intravenous injection of 68Ga-NY104.
Trial: NCT06613269
Drug: 18F-FDG PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F-FDG PET/CT will be performed at baseline and 6 months after radiation therapy. The scan begins 1 hour after intravenous injection of 18F-FDG.
Trial: NCT06613269
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy will be delivered to patients to control the tumor. Possible regimen includes targeted therapy alone, immunotherapy alone, and targeted therapy combined with immunotherapy. The treatment regimen will be decided according to the urology oncologist.
Trial: NCT06404541
Drug: Dexamethasone, tobramycin, netilimicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: Dexathalm single dose Group B: Tobradex Group C: Dexathalm multi-dose
Trial: NCT05824858
Drug: LY3537982
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT03070691
Drug: LDE225B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream, 2x daily
Trial: NCT03070691
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cream, 2x daily
Trial: NCT06446388
Drug: QLS31905
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an intravenous infusion.
Trial: NCT06590857
Drug: RYZ101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ac-225
Trial: NCT06446388
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2, oral, bid, D1-D14
Trial: NCT04737850
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with no active pharmaceutical ingredient
Trial: NCT05303935
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo sugar pill that looks like the quetiapine tablet taken at bedtime for one night.
Trial: NCT05389709
Drug: Iberogast (STW5-II, BAY98-7410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survey without any intervention assigned in the study.
Trial: NCT05359068
Drug: SPH3127 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet
Trial: NCT05359068
Drug: SPH3127 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets
Trial: NCT05359068
Drug: SPH3127 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 tablets
Trial: NCT06597019
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile normal saline (0.9% sodium chloride in water for subcutaneous injection)
Trial: NCT06443255
Drug: Cociane hydrochloride 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL of 4% cocaine
Trial: NCT06443255
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL of saline 0.9%
Trial: NCT05118360
Drug: ASC41 2 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2mg of ASC41 orally once daily for 52 weeks
Trial: NCT05118360
Drug: ASC41 4 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4mg of ASC41 orally once daily for 52 weeks
Trial: NCT05118360
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo orally once daily for 52 weeks.
Trial: NCT06121505
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive sintilimab combined with standard platinum-based doublet chemotherapy for a total of 4 cycles. Patients subsequently received maintenance treatment with sintilimab, and continued treatment until disease progression (PD), intolerable toxicity, withdrawal of informed consent, initiation of other anti-tumor treatments, death, or other circumstances that should stop treatment as specified in the protocol. Whichever occurs first. The maximum treatment time with sintilimab is 24 months (or 35 cycles).
Trial: NCT03680976
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid-filled capsule containing olive oil manufactured to mimic CXA-10 150 mg capsule
Trial: NCT06239714
Drug: SGB-3403
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGB-3403 is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
Trial: NCT04862884
Drug: HRS4800 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Drug: HRS4800 tablets Low-dose group, single oral administration~2. Drug: HRS4800 tablets Low-medium dose group, single oral administration~3. Drug: HRS4800 tablets medium -dose group, single oral administration~4. Drug: HRS4800 tablets Medium and high dose group, single oral administration~5. Drug: HRS4800 tablets High-dose group, single oral administration
Trial: NCT04862884
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Drug: placebo Low-dose group, single oral administration~2. Drug: placebo Low-medium dose group, single oral administration~3. Drug: placebo medium -dose group, single oral administration~4. Drug: placebo Medium and high dose group, single oral administration~5. Drug: placebo High-dose group, single oral administration
Trial: NCT05291052
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m2, orally, BID, D1-14, Q3W~Subjects can receive up to 8 cycles of the XELOX regimen (Oxaliplatin and Capecitabine). For subjects who are intolerant to XELOX regimen or have stable disease or objective response after complete 8 cycles of XELOX regimen, treatment with tisleizumab and lenvatinib will be continued until tumor progression or for a maximum of 2 years.
Trial: NCT06173596
Drug: ALXN2080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive ALXN2080 orally.
Trial: NCT05081336
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin +/- ezetimib +/- Alirocumab
Trial: NCT00002194
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002194
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05270928
Drug: IBI346
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI346 Antibody and IBI346 CAR-T cell injection
Trial: NCT05132569
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Film-coated tablet Route of administration: Oral
Trial: NCT05815082
Drug: FOLFOX chemotherapy regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
Trial: NCT06355479
Drug: OsrHSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant Human Serum Albumin from Oryza Sativa
Trial: NCT06355479
Drug: Plasbumin®-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin (Human) 20%, USP
Trial: NCT06588010
Drug: OM-89 [Uro-Vaxom® Capsule] OM-89 placebo [Uro-Vaxom® Capsule placebo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1st phase: 1 capsule per day of placebo for 90 consecutive days followed by a period of 90 days without treatment, then one capsule per day of placebo for 10 consecutive days each month for three months.~Then 2nd phase: 1 capsule a day of OM-89, for 90 consecutive days followed by a period of 90 days without treatment, then one capsule a day of OM-89 6mg for 10 consecutive days each month for three months.
Trial: NCT06678165
Drug: YOLT-204
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention group will receive YOLT-204 on day0
Trial: NCT06463717
Drug: Transplant, Autologous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose melphalan followed by autologous stem cell transplantation
Trial: NCT04134026
Drug: HIF-PHI
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug will be dosed orally three times a week.
Trial: NCT01556152
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo for 28 Days
Trial: NCT06412926
Drug: BAY 44-4400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet, oral use
Trial: NCT05523570
Drug: HNC364
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 subjects (both male and female) to receive 20 mg HNC364 intramuscular administration to evaluate the safety and tolerability of HNC364 injectable suspension. Then 8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 20 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
Trial: NCT05523570
Drug: HNC364
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 40 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
Trial: NCT05523570
Drug: HNC364
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 60 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
Trial: NCT05523570
Drug: HNC364
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 80 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
Trial: NCT06616974
Drug: TX000045- Dose B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will receive subcutaneous injection of Dose B of TX000045 every 4 weeks for 24 weeks where they will alternate between TX000045 and placebo every 2 weeks.
Trial: NCT06616974
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will receive a subcutaneous injection of placebo every 2 weeks for 24 weeks.
Trial: NCT05248984
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once the decision has been made by the primary obstetrics (OB) provider to proceed with cesarean delivery, participants will be randomized in to one of two groups:~* Single dose of intravenous (IV) Ketorolac 30mg Vs.~* Single dose of intravenous (IV) Ketorolac 60mg
Trial: NCT06287437
Drug: HRS9531
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS9531 escalated to the protocol-specified dose once weekly injection for 24 weeks ，then low frequency injection for 12 weeks.
Trial: NCT06287437
Drug: HRS9531 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS9531 placebo low frequency injection for 12 weeks.
Trial: NCT04701034
Drug: Human Intravenous Immunoglobulins, (Privigen (R), CLS Behring)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion: Initial infusion rate of 0.3 ml/kg BW/hr in about 30 min. If well-tolerated, the infusion rate may gradually be increased to 4.8 ml/kg BW/hr. During the infusion, health care personnel are present to secure immediate action in case of serious AR. Blood pressure and pulse is monitored before, during and after the treatment. In case of anaphylaxis, the treatment is discontinued and the participant is excluded. The hospital ward possess adrenaline 0.1 % solutions ready in case of anaphylaxis.
Trial: NCT04701034
Drug: Prednisolone Tablets
RxNorm normalized name: Prednisolone Tablets
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg before ET and 10 mg after ET until gestational week 8+0
Trial: NCT04701034
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet before ET and 2 tablets after ET until gestational week 8+0
Trial: NCT05585931
Drug: TPN171H 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were given 10mg TPN171H tablet with 240 mL warm water under fasting condition.
Trial: NCT05585931
Drug: TPN171H Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were given Placebo with 240 mL warm water under fasting condition.
Trial: NCT06580327
Drug: continuous epidural infusion
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the control group protocol for pain maintenance, i.e., 0.1% Bupivacaine and 2 μg/ml fentanyl as a continuous infusion per one hour, until the delivery is completed, and laceration is sutured. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score \>30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study.
Trial: NCT01161394
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04819906
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five placebo tablets orally once
Trial: NCT04880382
Drug: ICI treatment discontinuation
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After achieving objective response between 6 and 12 months after treatment onset, for these patients, first or second line treatment by immune checkpoint inhibitor will be discontinued. Patients will be followed as per standard mangement thereafter
Trial: NCT04880382
Drug: ICI treatment continuation
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After achieving objective response between 6 and 12 months after treatment onset, for these patients, first or second line treatment by immune checkpoint inhibitor will be continued until disease progreession or unacceptable toxicity
Trial: NCT05045313
Drug: DBPR108 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: DBPR108, tablet, oral
Trial: NCT05365659
Drug: IKS03
RxNorm normalized name: Ibuprofen Potassium Salicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent.
Trial: NCT06168318
Drug: VH4004280 Formulation B
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of VH4004280 Formulation B in fasted or fed conditions.
Trial: NCT06168318
Drug: VH4004280 Formulation D
RxNorm normalized name: Rho(D) Unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of VH4004280 Formulation D in fasted or fed conditions.
Trial: NCT05234320
Drug: CG-SpikeDown, intranasal formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The CG-SpikeDown peptide produces a dose-dependent increase in binding to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein and a dose-dependent inhibition of SARS-CoV-2 protein binding to ACE2, the key cellular target. A similar inhibition of binding to ACE2 in human alveolar basal epithelial cells has been demonstrated.
Trial: NCT04754802
Drug: Placebo Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray delivered 20 minutes before the public speaking stressor
Trial: NCT03239236
Drug: Anesthetics
RxNorm normalized name: ANESTHETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction agents will be administered as quick boluses (Propofol 2,5mg/kg total body weight, max 350mg, Fentanyl 250mcg, Rocuronium 1,2mg/kg ideal body weight).
Trial: NCT06290219
Drug: Zinc Gluconate 10 MG Oral Tablet
RxNorm normalized name: zinc gluconate 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet three times a day for a period of 12 weeks
Trial: NCT05754424
Drug: Humulin R 500 UNT/ML Injectable Solution
RxNorm normalized name: Humulin R 500 UNT/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular human insulin
Trial: NCT06014528
Drug: IN10018
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg QD orally (PO)
Trial: NCT06014528
Drug: Placebo of IN10018
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg QD orally (PO)
Trial: NCT06014528
Drug: Pegylated Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/m2 once every 4 weeks (Q4W) intravenously (IV)
Trial: NCT05201638
Drug: Placebo matching IMU-838 tablets
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are randomized to IMU-838 or placebo in ratio 1:1
Trial: NCT04845646
Drug: ASC41
RxNorm normalized name: Ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg/tablet
Trial: NCT04845646
Drug: Phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300mg/capsule
Trial: NCT05032326
Drug: Follow-up study of the treated cohort
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: follow-up study of the patients in the treated cohort: that have been included in the otbb3 study
Trial: NCT05022563
Drug: Parenteral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral anticoagulant only
Trial: NCT06616922
Drug: RD03/2016 eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop, 4 times a day (approximately every 4 hours while awake) for 5 days starting from Day 1.
Trial: NCT05445609
Drug: VLP-encapsulated TLR9 Agonist CMP-001,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given SC or IT
Trial: NCT04647383
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COPD: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
Trial: NCT05540873
Drug: YYB-103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological: IL13Rα2 CAR-T cells Administration method: intravenous infusion YYB-103 is manufactured according to the subject's assigned dose group and body weight.
Trial: NCT04858659
Drug: PK101-002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet at each time, 2 times a day
Trial: NCT04858659
Drug: PK101 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet at each time, 2 times a day
Trial: NCT04858659
Drug: PK101-002 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet at each time, 2 times a day